Research

Cellular

Gastrointestinal side effects were more common with GI181771X than with placebo treatment.

Clinicians should monitor for gastrointestinal side effects in patients taking GI181771X.

StrongSupportsmedium confidence
Gastrointestinal side effects were more common with GI181771X than with placebo treatment.
Jens Jordan et al. · Clinical Pharmacology & Therapeutics · 2007

Why this rating

Based on the randomized controlled trial design with a large sample size.

Source

Stimulation of Cholecystokinin-A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients

Jens Jordan et al. · Clinical Pharmacology & Therapeutics · 2007

DOI 10.1038/sj.clpt.6100272

rct · n=701Cited 118×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →